Loading
Not every survivor needs to see an oncologist every six months for years. Sort people by recurrence risk, send low-risk survivors back to their family doctor with a clear plan, and guarantee rapid return if something changes.
Hospital-based follow-up for all survivors consumes specialist capacity without evidence of survival benefit for most low-risk patients. Risk-stratified models (as in England's personalised stratified follow-up) move low-risk patients to supported self-management and primary care, with remote surveillance tests and an open re-access route, reserving specialist follow-up for high-risk patients. Randomised evidence shows equivalence for recurrence detection in breast and colorectal cancer.
Shares Nobody owns the follow-up once the oncology clinic lets go, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it, Survivorship and late effects are neglected.
Shares Report death from other causes as an outcome of the prostate cancer service, split by deprivation and ethnicity, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer, Prostate cancer.
Shares Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer.
Shares Nobody owns the follow-up once the oncology clinic lets go, Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it.
Shares Not enough oncologists, nurses, pathologists, physicists, HR-positive / HER2-negative breast cancer, Colorectal cancer.
Shares Not enough oncologists, nurses, pathologists, physicists, HR-positive / HER2-negative breast cancer, Colorectal cancer.
Shares Not enough oncologists, nurses, pathologists, physicists, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer, Prostate cancer.
Shares Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it.